Exact Mass: 311.2249024

Exact Mass Matches: 311.2249024

Found 242 metabolites which its exact mass value is equals to given mass value 311.2249024, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Biperiden

1-{bicyclo[2.2.1]hept-5-en-2-yl}-1-phenyl-3-(piperidin-1-yl)propan-1-ol

C21H29NO (311.2249024)


A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. [PubChem] D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders[1][2].

   

Spiradine A

6-Hydroxyhetisan-11-one

C20H25NO2 (311.188519)


   
   

17beta-Hydroxy-3-methoxyestra-1,3,5(10)-triene-17-carbonitrile

17beta-Hydroxy-3-methoxyestra-1,3,5(10)-triene-17-carbonitrile

C20H25NO2 (311.188519)


   

1-[(1R,4R)-5-bicyclo[2.2.1]hept-2-enyl]-1-phenyl-3-(1-piperidinyl)-1-propanol

1-[(1R,4R)-5-bicyclo[2.2.1]hept-2-enyl]-1-phenyl-3-(1-piperidinyl)-1-propanol

C21H29NO (311.2249024)


   

2-trans,4-cis-Decadienoylcarnitine

(3R)-3-[(2E,4Z)-Deca-2,4-dienoyloxy]-4-(trimethylazaniumyl)butanoic acid

C17H29NO4 (311.2096474)


2-trans,4-cis-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z)-deca-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-trans,4-cis-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-trans,4-cis-decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 2-trans,4-cis-decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

(2E,4Z)-Decadienoylcarnitine

3-[(2E,4Z)-Deca-2,4-dienoyloxy]-4-(trimethylammonio)butanoic acid

C17H29NO4 (311.2096474)


(2E,4Z)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4Z)-decadienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4Z)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,4Z)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2E,4Z)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3,8)-Decadienoylcarnitine

3-(deca-3,8-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(3,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2,6)-Decadienoylcarnitine

3-(deca-2,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(2,6)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,6)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,6)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,6)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3,6)-Decadienoylcarnitine

3-(deca-3,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(3,6)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,6)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,6)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,6)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6,8)-Decadienoylcarnitine

3-(deca-6,8-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(6,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-6,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (6,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3,5)-Decadienoylcarnitine

3-(deca-3,5-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(3,5)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,5)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,5)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,5)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2,8)-Decadienoylcarnitine

3-(deca-2,8-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(2,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4,6)-Decadienoylcarnitine

3-(deca-4,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(4,6)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4,6)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4,6)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4,6)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5,8)-Decadienoylcarnitine

3-(deca-5,8-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(5,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-5,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (5,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2,7)-Decadienoylcarnitine

3-(deca-2,7-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(2,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4,7)-Decadienoylcarnitine

3-(deca-4,7-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(4,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(5,7)-Decadienoylcarnitine

3-(deca-5,7-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(5,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (5,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (5,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4,8)-Decadienoylcarnitine

3-(deca-4,8-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(4,8)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-4,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4,8)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4,8)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4,8)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3,7)-Decadienoylcarnitine

3-(deca-3,7-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(3,7)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-3,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3,7)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3,7)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (3,7)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2,5)-Decadienoylcarnitine

3-(deca-2,5-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


(2,5)-Decadienoylcarnitine is an acylcarnitine. More specifically, it is an deca-2,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2,5)-Decadienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2,5)-Decadienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (2,5)-Decadienoylcarnitine is elevated in the blood or plasma of individuals with 2,4-dienoyl-coenzyme a reductase deficiency (PMID: 2332510, PMID: 15344554, PMID: 19578400). It is also decreased in the blood or plasma of individuals with familial mediterranean fever (PMID: 29900937) and schizophrenia (PMID: 31161852). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

C21H29NO (311.2249024)


   

1-(1-Pentyl-1h-indol-3-yl)-3-methyl-2-(propan-2-yl)but-3-en-1-one

1-(1-Pentyl-1h-indol-3-yl)-3-methyl-2-(propan-2-yl)but-3-en-1-one

C21H29NO (311.2249024)


   

Butofilolol

1-{2-[3-(tert-butylamino)-2-hydroxypropoxy]-5-fluorophenyl}butan-1-one

C17H26FNO3 (311.18966180000007)


   

Dienogest

2-{14-hydroxy-15-methyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-14-yl}acetonitrile

C20H25NO2 (311.188519)


   

Dimepheptanol

(3R,6R)-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane

C21H29NO (311.2249024)


   

Femoxetine

trans-3-((4-Methoxyphenoxy)methyl)-1-methyl-4-phenylpiperidine

C20H25NO2 (311.188519)


   

Val-pro-pro

1-[1-(2-amino-3-methylbutanoyl)pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid

C15H25N3O4 (311.184497)


   

Norpropoxyphene amide

N-(3-Hydroxy-2-methyl-3,4-diphenylbutyl)propanimidate

C20H25NO2 (311.188519)


   

Dinorpropoxyphene

4-Amino-3-methyl-1,2-diphenylbutan-2-yl propanoic acid

C20H25NO2 (311.188519)


   

(9S,10E,12Z)-9-hydroperoxy-10,12-octadecadienoate

(10E,12Z)-(9S)-9-Hydroperoxyoctadeca-10,12-dienoic acid

C18H31O4 (311.2222226)


(9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate, also known as 9(S)-hydroperoxy-10(E),12(z)-octadecadienoic acid or 9(S)-hpod(1-), belongs to lineolic acids and derivatives class of compounds. Those are derivatives of lineolic acid. Lineolic acid is a polyunsaturated omega-6 18 carbon long fatty acid, with two CC double bonds at the 9- and 12-positions (9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). (9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate can be found in a number of food items such as mexican groundcherry, brazil nut, coconut, and winter savory, which makes (9s,10e,12z)-9-hydroperoxy-10,12-octadecadienoate a potential biomarker for the consumption of these food products.

   
   

6-Methoxydictyolomide A

(+)-6-Methoxydictyolomide A

C20H25NO2 (311.188519)


   

CJ 13568

(E)-(-)-2-(3-Hydroxy-3,7-dimethyl-1,6-octadienyl)-1-methyl-4(1H)-quinolinone

C20H25NO2 (311.188519)


   

(Z)-1-Methyl-2-(undec-5-enyl)quinolin-4-one

(Z)-1-Methyl-2-(undec-5-enyl)quinolin-4-one

C21H29NO (311.2249024)


   
   

CJ 13567

(E)-(+)-2-(1-hydroxy-3,7-dimethyl-2,6-octadienyl)-1-methyl-4(1H)-1uinolinone

C20H25NO2 (311.188519)


   
   

1-Methyl-2-[(Z)-6-undecenyl]quinolin-4-one

1-Methyl-2-[(Z)-6-undecenyl]quinolin-4-one

C21H29NO (311.2249024)


   
   

11-Dehydrokobusine

11-Dehydrokobusine

C20H25NO2 (311.188519)


   
   

Dienogest

Dienogest

C20H25NO2 (311.188519)


G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DB - Pregnadien derivatives C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D000970 - Antineoplastic Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3284

   
   
   

adiphenine

2-(diethylamino)ethyl 2,2-diphenylacetate

C20H25NO2 (311.188519)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

N-Tetradecanoyl-DL-homoserine lactone

N-Tetradecanoyl-DL-homoserine lactone

C18H33NO3 (311.24603079999997)


   
   
   
   

1-methyl-2-(3-hydroxy-3,7-dimethyl-octa-1,6-dienyl)quinolin-4(1h)-one

1-methyl-2-(3-hydroxy-3,7-dimethyl-octa-1,6-dienyl)quinolin-4(1h)-one

C20H25NO2 (311.188519)


   
   

2-[2-(3,4-dimethoxyphenyl)ethyl]-1-methyl-3,4-dihydro-2H-quinoline

2-[2-(3,4-dimethoxyphenyl)ethyl]-1-methyl-3,4-dihydro-2H-quinoline

C20H25NO2 (311.188519)


   

seco-pseudopteroxazole

seco-pseudopteroxazole

C21H29NO (311.2249024)


A natural product found in Pseudopterogorgia elisabethae.

   

1-methyl-2-[(E)-1-undecenyl]-4(1H)-quinolone|1-methyl-2-[(E)-1-undecenyl]-4(1H)-quinolone

1-methyl-2-[(E)-1-undecenyl]-4(1H)-quinolone|1-methyl-2-[(E)-1-undecenyl]-4(1H)-quinolone

C21H29NO (311.2249024)


   
   
   

cucurbinoyl-isoleucine

cucurbinoyl-isoleucine

C17H29NO4 (311.2096474)


   
   
   

1-Methyl-2-(undec-6-en-1-yl)quinolin-4(1H)-one

1-Methyl-2-(undec-6-en-1-yl)quinolin-4(1H)-one

C21H29NO (311.2249024)


   
   

1-methyl-2-undec-6-enylquinolin-4-one

1-Methyl-2-(undec-6-en-1-yl)quinolin-4(1H)-one

C21H29NO (311.2249024)


   

1-Methyl-2-[(Z)-5-undecenyl]-4(1H)-quinolone

4(1H)-Quinolinone, 1-methyl-2-(5Z)-5-undecen-1-yl-

C21H29NO (311.2249024)


   

C21H29NO_1-Methyl-2-[(6Z)-6-undecen-1-yl]-4(1H)-quinolinone

NCGC00385992-01_C21H29NO_1-Methyl-2-[(6Z)-6-undecen-1-yl]-4(1H)-quinolinone

C21H29NO (311.2249024)


   

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone

C21H29NO (311.2249024)


   
   

C14-homoserine lactone

N-(2-oxooxolan-3-yl)tetradecanamide

C18H33NO3 (311.24603079999997)


CONFIDENCE standard compound; INTERNAL_ID 206

   

biperiden

biperiden

C21H29NO (311.2249024)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders[1][2].

   

deoxycommendamide (putative) or in source fragment -H2O observed in AGP sample

deoxycommendamide (putative) or in source fragment -H2O observed in AGP sample

C18H33NO3 (311.24603079999997)


   

(dehydrohexadecanoyl)glycine - Commendamide analogue

(dehydrohexadecanoyl)glycine - Commendamide analogue

C18H33NO3 (311.24603079999997)


   
   

17-hydroxy-3-oxo-, (17??)-19-Norpregna-5(10),9(11)-diene-21-nitrile

17-hydroxy-3-oxo-, (17??)-19-Norpregna-5(10),9(11)-diene-21-nitrile

C20H25NO2 (311.188519)


   
   
   

Dinorpropoxyphene

Dinorpropoxyphene

C20H25NO2 (311.188519)


   

(7R,8R,E)-6-((2R)-7-hydroxy-2,6-dimethylheptylidene)-8-methyloctahydroindolizine-7,8-diol

(7R,8R,E)-6-((2R)-7-hydroxy-2,6-dimethylheptylidene)-8-methyloctahydroindolizine-7,8-diol

C18H33NO3 (311.24603079999997)


   
   

TDHL

N-[(3S)-tetrahydro-2-oxo-3-furanyl]-tetradecanamide

C18H33NO3 (311.24603079999997)


   

CAR 10:2

3-[(2E,4Z)-deca-2,4-dienoyloxy]-4-(trimethylammonio)butanoate;cis-4-trans-2-decadienoylcarnitine

C17H29NO4 (311.2096474)


   

C14-HSL

N-tetradecanoyl-homoserine lactone

C18H33NO3 (311.24603079999997)


   

Alphamethadol

Alphamethadol

C21H29NO (311.2249024)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent

   
   

Butofilolol

Butofilolol

C17H26FNO3 (311.18966180000007)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   
   
   

2-Ethylhexyl 2-cyano-5-phenyl-2,4-pentadienoate

2-Ethylhexyl 2-cyano-5-phenyl-2,4-pentadienoate

C20H25NO2 (311.188519)


   

tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylate

tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylate

C16H30BNO4 (311.226777)


   

2-(3-(tert-butoxycarbonyl)-3-azaspiro[5.5]undecane-9-yl)acetic acid

2-(3-(tert-butoxycarbonyl)-3-azaspiro[5.5]undecane-9-yl)acetic acid

C17H29NO4 (311.2096474)


   

(1R, 2R)-Pseudoephedrine-(S)-2-methylhydrocinnamamide

(1R, 2R)-Pseudoephedrine-(S)-2-methylhydrocinnamamide

C20H25NO2 (311.188519)


   

(3S,6R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol

(3S,6R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol

C21H29NO (311.2249024)


   

N-(3-methoxyphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide

N-(3-methoxyphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide

C20H25NO2 (311.188519)


   

buta-1,3-diene,methyl 2-methylprop-2-enoate,prop-2-enenitrile,styrene

buta-1,3-diene,methyl 2-methylprop-2-enoate,prop-2-enenitrile,styrene

C20H25NO2 (311.188519)


   

(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-Methylpentanoate

(2R,4S)-ethyl 5-([1,1-biphenyl]-4-yl)-4-amino-2-Methylpentanoate

C20H25NO2 (311.188519)


   
   

Benzyldimethyldecylammonium chloride purum,

Benzyldimethyldecylammonium chloride purum,

C19H34ClN (311.23796340000007)


   
   

N-BENZYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE

N-BENZYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIMIDIN-2-AMINE

C17H22BN3O2 (311.1804982)


   
   

Femoxetine

Femoxetine

C20H25NO2 (311.188519)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D049990 - Membrane Transport Modulators D000890 - Anti-Infective Agents

   

Fomocaine

4-[3-[4-(phenoxymethyl)phenyl]propyl]morpholine

C20H25NO2 (311.188519)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   

Acetamide,N-(2-chlorophenyl)-2-[[2-(diethylamino)ethyl]ethylamino]-

Acetamide,N-(2-chlorophenyl)-2-[[2-(diethylamino)ethyl]ethylamino]-

C16H26ClN3O (311.1764296)


   

(S)-Di-tert-butyl2-cyanopiperazine-1,4-dicarboxylate

(S)-Di-tert-butyl2-cyanopiperazine-1,4-dicarboxylate

C15H25N3O4 (311.184497)


   
   
   
   
   

Butanoic acid, 4-[bis(phenylmethyl)amino]-, ethyl ester

Butanoic acid, 4-[bis(phenylmethyl)amino]-, ethyl ester

C20H25NO2 (311.188519)


   

1-{4-[(2-Ethoxyethoxy)methyl]phenoxy}-3-(isopropylamino)-2-propanol

1-{4-[(2-Ethoxyethoxy)methyl]phenoxy}-3-(isopropylamino)-2-propanol

C17H29NO4 (311.2096474)


   

Benzenamine, 5-chloro-2-(dodecyloxy)-

Benzenamine, 5-chloro-2-(dodecyloxy)-

C18H30ClNO (311.20158000000004)


   

trans-1-(tert-butoxycarbonyl)-4-(cyclohexylmethyl)pyrrolidine-3-carboxylic acid

trans-1-(tert-butoxycarbonyl)-4-(cyclohexylmethyl)pyrrolidine-3-carboxylic acid

C17H29NO4 (311.2096474)


   
   

2-Methoxyoestra-1,3,5(10),16-tetraene-3-carboxamide

2-Methoxyoestra-1,3,5(10),16-tetraene-3-carboxamide

C20H25NO2 (311.188519)


   
   

Val-pro-pro

Val-pro-pro

C15H25N3O4 (311.184497)


D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors A tripeptide composed of L-valine and two L-proline units joined by peptide linkages. H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM. H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM. H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.

   

Ambutonium

Ambutonium

C20H27N2O+ (311.2123272)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

1,7,7-Trimethyl-4-[(2-methyl-2,3-dihydroindol-1-yl)-oxomethyl]-2-bicyclo[2.2.1]heptanone

1,7,7-Trimethyl-4-[(2-methyl-2,3-dihydroindol-1-yl)-oxomethyl]-2-bicyclo[2.2.1]heptanone

C20H25NO2 (311.188519)


   

(S)-3-Oxo-N-(2-oxotetrahydrofuran-3-yl)tridecanamide

(S)-3-Oxo-N-(2-oxotetrahydrofuran-3-yl)tridecanamide

C17H29NO4 (311.2096474)


   

(Z)-1-Methyl-2-(undec-6-enyl)quinolin-4(1H)-one

(Z)-1-Methyl-2-(undec-6-enyl)quinolin-4(1H)-one

C21H29NO (311.2249024)


   

13(S)-Hpode(1-)

13(S)-Hpode(1-)

C18H31O4- (311.2222226)


Conjugate base of 13(S)-HPODE arising from deprotonation of the carboxylic acid function.

   

(9S,10E,12Z)-9-Hydroperoxy-10,12-octadecadienoate

(9S,10E,12Z)-9-Hydroperoxy-10,12-octadecadienoate

C18H31O4- (311.2222226)


   

(8R,9Z,12Z)-8-Hydroperoxyoctadeca-9,12-dienoate

(8R,9Z,12Z)-8-Hydroperoxyoctadeca-9,12-dienoate

C18H31O4- (311.2222226)


   

(11S)-11-Hydroperoxylinoleate

(11S)-11-Hydroperoxylinoleate

C18H31O4- (311.2222226)


Conjugate base of (11S)-11-hydroperoxylinoleic acid arising from deprotonation of the carboxylic acid function.

   

(9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate

(9R,10E,12Z)-9-hydroperoxyoctadeca-10,12-dienoate

C18H31O4- (311.2222226)


   

5(S),8(R)-DiHODE(1-)

5(S),8(R)-DiHODE(1-)

C18H31O4- (311.2222226)


A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of 5(S),8(R)-DiHODE. The major species at pH 7.3.

   

(8E,10R,12Z)-10-Hydroperoxy-8,12-octadecadienoate

(8E,10R,12Z)-10-Hydroperoxy-8,12-octadecadienoate

C18H31O4- (311.2222226)


The hydroperoxy fatty acid anion that is the conjugate base of hydroperoxy fatty acid anion, formed by deprotonation of the carboxy group; principal microspecies at pH 7.3.

   

(8E,10S,12Z)-10-hydroperoxyoctadeca-8,12-dienoate

(8E,10S,12Z)-10-hydroperoxyoctadeca-8,12-dienoate

C18H31O4- (311.2222226)


An unsaturated fatty acid anion that is the conjugate base of (8E,10S,12Z)-10-hydroperoxyoctadeca-8,12-dienoic acid, obtained by deprotonation of the carboxy group.

   

(12Z,15Z)-9,10-dihydroxyoctadeca-12,15-dienoic acid

(12Z,15Z)-9,10-dihydroxyoctadeca-12,15-dienoic acid

C18H31O4- (311.2222226)


   

9-Hydroxy-10-oxo-12-octadecenoate

9-Hydroxy-10-oxo-12-octadecenoate

C18H31O4- (311.2222226)


   

(9Z,11E,13R)-13-hydroperoxyoctadecadienoate

(9Z,11E,13R)-13-hydroperoxyoctadecadienoate

C18H31O4- (311.2222226)


   

(9Z,15Z)-12,13-Dihydroxyoctadeca-9,15-dienoate

(9Z,15Z)-12,13-Dihydroxyoctadeca-9,15-dienoate

C18H31O4- (311.2222226)


   

(9Z,12Z)-15,16-Dihydroxyoctadeca-9,12-dienoate

(9Z,12Z)-15,16-Dihydroxyoctadeca-9,12-dienoate

C18H31O4- (311.2222226)


   

8-[3-[(3-Pentyloxiran-2-yl)methyl]oxiran-2-yl]octanoate

8-[3-[(3-Pentyloxiran-2-yl)methyl]oxiran-2-yl]octanoate

C18H31O4- (311.2222226)


   

10-oxo-13-Hydroxy-11-octadecenoate

10-oxo-13-Hydroxy-11-octadecenoate

C18H31O4- (311.2222226)


   

(7S,8S,9Z,12Z)-7,8-dihydroxy-9,12-octadecadienoate

(7S,8S,9Z,12Z)-7,8-dihydroxy-9,12-octadecadienoate

C18H31O4- (311.2222226)


   

(3,8)-Decadienoylcarnitine

(3,8)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(2,6)-Decadienoylcarnitine

(2,6)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(3,6)-Decadienoylcarnitine

(3,6)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(6,8)-Decadienoylcarnitine

(6,8)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(3,5)-Decadienoylcarnitine

(3,5)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(2,8)-Decadienoylcarnitine

(2,8)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(4,6)-Decadienoylcarnitine

(4,6)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(5,8)-Decadienoylcarnitine

(5,8)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(2,7)-Decadienoylcarnitine

(2,7)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(4,7)-Decadienoylcarnitine

(4,7)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(5,7)-Decadienoylcarnitine

(5,7)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(4,8)-Decadienoylcarnitine

(4,8)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(3,7)-Decadienoylcarnitine

(3,7)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

(2,5)-Decadienoylcarnitine

(2,5)-Decadienoylcarnitine

C17H29NO4 (311.2096474)


   

13-HPODE(1-)

13-HPODE(1-)

C18H31O4- (311.2222226)


A hydroperoxy fatty acid anion that is the conjugate base of 13-HPODE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.

   

9-hydroperoxy-(10E,12Z)-octadecadienoate

9-hydroperoxy-(10E,12Z)-octadecadienoate

C18H31O4- (311.2222226)


   
   

(17

A)-17-Hydroxy-3-oxo-19-norpregna-5(10),9(11)-diene-21-nitrile

C20H25NO2 (311.188519)


   

7(S),8(S)-DiHODE(1-)

7(S),8(S)-DiHODE(1-)

C18H31O4- (311.2222226)


Conjugate base of 7(S),8(S)-DiHODE arising from deprotonation of the carboxylic acid function.

   

1-(1-Methylcyclopentyl)-1-phenyl-4-(1-piperidinyl)-2-butyn-1-ol

1-(1-Methylcyclopentyl)-1-phenyl-4-(1-piperidinyl)-2-butyn-1-ol

C21H29NO (311.2249024)


   

11-hydroxy-(12S,13S)-epoxy-(9Z)-octadecenoate(1-)

11-hydroxy-(12S,13S)-epoxy-(9Z)-octadecenoate(1-)

C18H31O4- (311.2222226)


A monounsaturated fatty acid anion that is the conjugate base of 11-hydroxy-(12S,13S)-epoxy-(9Z)-octadecenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(11R)-hydroperoxy-(9Z,12Z)-octadecadienoate

(11R)-hydroperoxy-(9Z,12Z)-octadecadienoate

C18H31O4- (311.2222226)


   

(2R,9Z,12Z)-2-hydroperoxyoctadecadienoate

(2R,9Z,12Z)-2-hydroperoxyoctadecadienoate

C18H31O4- (311.2222226)


   

8-{3-[(2Z)-8-hydroxyoct-2-en-1-yl]oxiran-2-yl}octanoate

8-{3-[(2Z)-8-hydroxyoct-2-en-1-yl]oxiran-2-yl}octanoate

C18H31O4- (311.2222226)


   

(9Z)-11-[3-(5-hydroxypentyl)oxiran-2-yl]undec-9-enoate

(9Z)-11-[3-(5-hydroxypentyl)oxiran-2-yl]undec-9-enoate

C18H31O4- (311.2222226)


   
   
   

4-(4-phenylmethoxyphenoxy)-N-prop-2-enyl-1-butanamine

4-(4-phenylmethoxyphenoxy)-N-prop-2-enyl-1-butanamine

C20H25NO2 (311.188519)


   
   

Ibogaine(1+)

Ibogaine(1+)

C20H27N2O+ (311.2123272)


A tertiary ammonium ion resulting from the protonation of the tertiary amino group of ibogaine.

   

1-[(1S,4S)-2-bicyclo[2.2.1]hept-5-enyl]-1-phenyl-3-piperidin-1-ylpropan-1-ol

1-[(1S,4S)-2-bicyclo[2.2.1]hept-5-enyl]-1-phenyl-3-piperidin-1-ylpropan-1-ol

C21H29NO (311.2249024)


   

(4S)-4-[(2E,4Z)-2,4-Decadienoyloxy]-4-(trimethylammonio)butanoate

(4S)-4-[(2E,4Z)-2,4-Decadienoyloxy]-4-(trimethylammonio)butanoate

C17H29NO4 (311.2096474)


   

(dehydrohexadecanoyl)glycine-Commendamide analogue

(dehydrohexadecanoyl)glycine-Commendamide analogue

C18H33NO3 (311.24603079999997)


   

(2S)-2-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide

(2S)-2-Amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridinyl)propyl]propanamide

C19H25N3O (311.199752)


   

7,8-dihydroxy-(9Z,12Z)-octadecadienoate

7,8-dihydroxy-(9Z,12Z)-octadecadienoate

C18H31O4- (311.2222226)


   

(5S)-hydroperoxy-(6E,8Z)-octadecadienoate

(5S)-hydroperoxy-(6E,8Z)-octadecadienoate

C18H31O4- (311.2222226)


   

N-ethyl-N-(3-methylphenyl)-N-(7H-purin-1-ium-6-yl)propane-1,3-diamine

N-ethyl-N-(3-methylphenyl)-N-(7H-purin-1-ium-6-yl)propane-1,3-diamine

C17H23N6+ (311.1984098)


   

(10R,11R)-epoxy-(9S)-hydroxy-(12Z)-octadecenoate

(10R,11R)-epoxy-(9S)-hydroxy-(12Z)-octadecenoate

C18H31O4- (311.2222226)


   

(12S,13R)-epoxy-(10R)-hydroxy-(8E)-octadecenoate

(12S,13R)-epoxy-(10R)-hydroxy-(8E)-octadecenoate

C18H31O4- (311.2222226)


   

(12R,13R)-epoxy-(11S)-hydroxy-(9Z)-octadecenoate

(12R,13R)-epoxy-(11S)-hydroxy-(9Z)-octadecenoate

C18H31O4- (311.2222226)


   

(3S)-3-[(2E,4Z)-deca-2,4-dienoyl]oxy-4-(trimethylazaniumyl)butanoate

(3S)-3-[(2E,4Z)-deca-2,4-dienoyl]oxy-4-(trimethylazaniumyl)butanoate

C17H29NO4 (311.2096474)


   

(5S,18)-dihydroxy-(6E,8Z)-octadecadienoate

(5S,18)-dihydroxy-(6E,8Z)-octadecadienoate

C18H31O4- (311.2222226)


   

(11S)-hydroxy-(9S,10S)-epoxy-(12Z)-octadecenoate

(11S)-hydroxy-(9S,10S)-epoxy-(12Z)-octadecenoate

C18H31O4- (311.2222226)


   

(12S,13S)-epoxy-(11R)-hydroxy-(9Z)-octadecenoate

(12S,13S)-epoxy-(11R)-hydroxy-(9Z)-octadecenoate

C18H31O4- (311.2222226)


   

(11R)-hydroxy-(9S,10S)-epoxy-(12Z)-octadecenoate

(11R)-hydroxy-(9S,10S)-epoxy-(12Z)-octadecenoate

C18H31O4- (311.2222226)


   

11-Hydroxy-12,13-epoxy-(9cis)-octadecenoate

11-Hydroxy-12,13-epoxy-(9cis)-octadecenoate

C18H31O4- (311.2222226)


   

2-[(8S,13R,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile

2-[(8S,13R,14S,17R)-17-hydroxy-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl]acetonitrile

C20H25NO2 (311.188519)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]propanamide

C18H33NO3 (311.24603079999997)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]acetamide

C18H33NO3 (311.24603079999997)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]pentanamide

C18H33NO3 (311.24603079999997)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]butanamide

C18H33NO3 (311.24603079999997)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]hexanamide

C18H33NO3 (311.24603079999997)


   

3-(1,3,6-Trimethyl-3-piperiden-4-yl)-2-(2-methyl-2-aminopropyl)indole

3-(1,3,6-Trimethyl-3-piperiden-4-yl)-2-(2-methyl-2-aminopropyl)indole

C20H29N3 (311.2361354)


   

9(S)-HPODE(1-)

9(S)-HPODE(1-)

C18H31O4 (311.2222226)


A monocarboxylic acid anion obtained by removal of a proton from the carboxylic acid group of 9(S)-HPODE.

   

8(R)-HPODE(1-)

8(R)-HPODE(1-)

C18H31O4 (311.2222226)


A monocarboxylic acid anion resulting from the deprotonation of the carboxy group of 8(R)-HPODE. The major species at pH 7.3.

   

9(R)-HPODE(1-)

9(R)-HPODE(1-)

C18H31O4 (311.2222226)


A monocarboxylic acid anion obtained by removal of a proton from the carboxylic acid group of 9(R)-HPODE.

   

13(R)-HPODE(1-)

13(R)-HPODE(1-)

C18H31O4 (311.2222226)


A 13-HPODE(1-) that is the conjugate base of 13(R)-HPODE, obtained by deprotonation of the carboxylic acid function. Major microspecies at pH 7.3.

   

(2E,4Z)-decadienoylcarnitine

(2E,4Z)-decadienoylcarnitine

C17H29NO4 (311.2096474)


An O-acylcarnitine having (2E,4Z)-decadienoyl as the acyl substituent.

   

N-(2-oxooxolan-3-yl)tetradecanamide

N-(2-oxooxolan-3-yl)tetradecanamide

C18H33NO3 (311.24603079999997)


   

N-[(9Z)-hexadecenoyl]glycine

N-[(9Z)-hexadecenoyl]glycine

C18H33NO3 (311.24603079999997)


A fatty acid amide resulting from the formal condensation of the carboxy group of (9Z)-hexadecenoic acid with the amino group of glycine.

   

O-decadienoylcarnitine

O-decadienoylcarnitine

C17H29NO4 (311.2096474)


An O-acylcarnitine in which the acyl group specified is decadienoyl in which the positions of the double bonds is unspecified..

   

O-decadienoyl-L-carnitine

O-decadienoyl-L-carnitine

C17H29NO4 (311.2096474)


An O-acyl-L-carnitine that is L-carnitine having decadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.

   
   
   

2-[(2e)-1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]-1-methylquinolin-4-one

2-[(2e)-1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]-1-methylquinolin-4-one

C20H25NO2 (311.188519)


   

(1s,5s,8r,9s,11r,13r,14r,16s,17r,18s)-13-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

(1s,5s,8r,9s,11r,13r,14r,16s,17r,18s)-13-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

C20H25NO2 (311.188519)


   

16-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

16-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

C20H25NO2 (311.188519)


   

1-methyl-2-(5-undecenyl)-4(1h)-quinolinone

NA

C21H29NO (311.2249024)


{"Ingredient_id": "HBIN002732","Ingredient_name": "1-methyl-2-(5-undecenyl)-4(1h)-quinolinone","Alias": "NA","Ingredient_formula": "C21H29NO","Ingredient_Smile": "NA","Ingredient_weight": "311.466","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9165","PubChem_id": "NA","DrugBank_id": "NA"}

   

1-methyl-2-(6-undecenyl)-4(1h)-quinolinone

NA

C21H29NO (311.2249024)


{"Ingredient_id": "HBIN002735","Ingredient_name": "1-methyl-2-(6-undecenyl)-4(1h)-quinolinone","Alias": "NA","Ingredient_formula": "C21H29NO","Ingredient_Smile": "NA","Ingredient_weight": "311.466","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "9162","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-ethyl-n-{[(2-ethyl-1-hydroxyhexylidene)amino]methanimidoyl}hexanimidic acid

2-ethyl-n-{[(2-ethyl-1-hydroxyhexylidene)amino]methanimidoyl}hexanimidic acid

C17H33N3O2 (311.2572638)


   

6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C21H29NO (311.2249024)


   

(1s,5r,8r,9s,10r,11s,14s,16s,17r,18r)-10-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

(1s,5r,8r,9s,10r,11s,14s,16s,17r,18r)-10-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

C20H25NO2 (311.188519)


   

3-(12-carboxy-1-hydroxydodecyl)-2-isocyano-2-methyloxirane

3-(12-carboxy-1-hydroxydodecyl)-2-isocyano-2-methyloxirane

C17H29NO4 (311.2096474)


   

1-methyl-3,3-bis(3-methylbut-2-en-1-yl)quinoline-2,4-dione

1-methyl-3,3-bis(3-methylbut-2-en-1-yl)quinoline-2,4-dione

C20H25NO2 (311.188519)


   

(5s,7r,7ar)-2-(2,4-dihydroxybutyl)-3-imino-5-(2-methylprop-1-en-1-yl)-tetrahydro-1h-pyrrolo[1,2-c]imidazole-7-carboxylic acid

(5s,7r,7ar)-2-(2,4-dihydroxybutyl)-3-imino-5-(2-methylprop-1-en-1-yl)-tetrahydro-1h-pyrrolo[1,2-c]imidazole-7-carboxylic acid

C15H25N3O4 (311.184497)


   

2-[(1s,2e)-1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]-1-methylquinolin-4-one

2-[(1s,2e)-1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl]-1-methylquinolin-4-one

C20H25NO2 (311.188519)


   

(2r,3r)-3-[(1r)-12-carboxy-1-hydroxydodecyl]-2-isocyano-2-methyloxirane

(2r,3r)-3-[(1r)-12-carboxy-1-hydroxydodecyl]-2-isocyano-2-methyloxirane

C17H29NO4 (311.2096474)


   

4,9-dimethyl-6-(6-methylhept-5-en-2-yl)-6h,7h,8h,9h-naphtho[2,1-d][1,3]oxazole

4,9-dimethyl-6-(6-methylhept-5-en-2-yl)-6h,7h,8h,9h-naphtho[2,1-d][1,3]oxazole

C21H29NO (311.2249024)


   

2-[(1e)-3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl]-1-methylquinolin-4-one

2-[(1e)-3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl]-1-methylquinolin-4-one

C20H25NO2 (311.188519)


   

10-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

10-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

C20H25NO2 (311.188519)


   

(3e,5e,7e,11e,13z,15e,17e)-19-methyl-1-azacycloicosa-1,3,5,7,11,13,15,17-octaene-2,10-diol

(3e,5e,7e,11e,13z,15e,17e)-19-methyl-1-azacycloicosa-1,3,5,7,11,13,15,17-octaene-2,10-diol

C20H25NO2 (311.188519)


   

(2r)-2-ethyl-n-({[(2r)-2-ethyl-1-hydroxyhexylidene]amino}methanimidoyl)hexanimidic acid

(2r)-2-ethyl-n-({[(2r)-2-ethyl-1-hydroxyhexylidene]amino}methanimidoyl)hexanimidic acid

C17H33N3O2 (311.2572638)


   

n-[(3s)-2-oxooxolan-3-yl]tetradecanimidic acid

n-[(3s)-2-oxooxolan-3-yl]tetradecanimidic acid

C18H33NO3 (311.24603079999997)


   

(1s,5r,8r,9s,11r,14s,16r,17r,18r)-16-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

(1s,5r,8r,9s,11r,14s,16r,17r,18r)-16-hydroxy-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-one

C20H25NO2 (311.188519)


   

(2r)-2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

(2r)-2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

C20H25NO2 (311.188519)


   

2-(hex-3-en-1-yl)-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

2-(hex-3-en-1-yl)-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

C20H25NO2 (311.188519)


   

(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-14,17-dien-16-one

C21H29NO (311.2249024)


   

2-(1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-1-methylquinolin-4-one

2-(1-hydroxy-3,7-dimethylocta-2,6-dien-1-yl)-1-methylquinolin-4-one

C20H25NO2 (311.188519)


   

2-[3-(2-hexylcyclopropyl)propyl]-1h-quinolin-4-one

2-[3-(2-hexylcyclopropyl)propyl]-1h-quinolin-4-one

C21H29NO (311.2249024)


   

1-isocyano-1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene

1-isocyano-1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene

C21H29NO (311.2249024)


   

(2s)-2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

(2s)-2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

C20H25NO2 (311.188519)


   

(1s,4s,4as,8as)-1,6-dimethyl-4-[(6s)-6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene-1-carbonitrile

(1s,4s,4as,8as)-1,6-dimethyl-4-[(6s)-6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene-1-carbonitrile

C21H29NO (311.2249024)


   

(6r,9s)-4,9-dimethyl-6-[(2s)-6-methylhept-5-en-2-yl]-6h,7h,8h,9h-naphtho[2,1-d][1,3]oxazole

(6r,9s)-4,9-dimethyl-6-[(2s)-6-methylhept-5-en-2-yl]-6h,7h,8h,9h-naphtho[2,1-d][1,3]oxazole

C21H29NO (311.2249024)


   

(2r)-2-ethyl-n-({[(2s)-2-ethyl-1-hydroxyhexylidene]amino}methanimidoyl)hexanimidic acid

(2r)-2-ethyl-n-({[(2s)-2-ethyl-1-hydroxyhexylidene]amino}methanimidoyl)hexanimidic acid

C17H33N3O2 (311.2572638)


   
   

1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene-1-carbonitrile

1,6-dimethyl-4-[6-(prop-1-en-2-yl)-5,6-dihydro-2h-pyran-3-yl]-3,4,4a,7,8,8a-hexahydro-2h-naphthalene-1-carbonitrile

C21H29NO (311.2249024)


   

6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-17,19-dien-16-one

6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-17,19-dien-16-one

C21H29NO (311.2249024)


   

2-(3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl)-1-methylquinolin-4-one

2-(3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl)-1-methylquinolin-4-one

C20H25NO2 (311.188519)


   

(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,17-dien-16-one

(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-7,17-dien-16-one

C21H29NO (311.2249024)


   

5-ethyl-4,5-dihydroxy-1-methyl-3-(2-methylnonanoyl)pyrrol-2-one

5-ethyl-4,5-dihydroxy-1-methyl-3-(2-methylnonanoyl)pyrrol-2-one

C17H29NO4 (311.2096474)


   

(2s,3s)-3-[(1s)-12-carboxy-1-hydroxydodecyl]-2-isocyano-2-methyloxirane

(2s,3s)-3-[(1s)-12-carboxy-1-hydroxydodecyl]-2-isocyano-2-methyloxirane

C17H29NO4 (311.2096474)


   

(8ar)-6,8a-diisopropyl-2,2,4-trimethyl-8h,9h-cyclopenta[g]quinolin-7-one

(8ar)-6,8a-diisopropyl-2,2,4-trimethyl-8h,9h-cyclopenta[g]quinolin-7-one

C21H29NO (311.2249024)


   

(10r,19s)-10-hydroxy-19-methyl-1-azacycloicosa-3,5,7,11,13,15,17-heptaen-2-one

(10r,19s)-10-hydroxy-19-methyl-1-azacycloicosa-3,5,7,11,13,15,17-heptaen-2-one

C20H25NO2 (311.188519)


   

n-(2-oxooxolan-3-yl)tetradecanimidic acid

n-(2-oxooxolan-3-yl)tetradecanimidic acid

C18H33NO3 (311.24603079999997)


   

2-[(1e,3r)-3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl]-1-methylquinolin-4-one

2-[(1e,3r)-3-hydroxy-3,7-dimethylocta-1,6-dien-1-yl]-1-methylquinolin-4-one

C20H25NO2 (311.188519)


   

2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

2-[(3z)-hex-3-en-1-yl]-8-methoxy-1h,2h,3h,4h-pyrido[1,2-a]quinolin-6-one

C20H25NO2 (311.188519)


   

(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-17,19-dien-16-one

(1r,2s,5s,6s,9r,12s,13r)-6,13-dimethyl-7-azapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-17,19-dien-16-one

C21H29NO (311.2249024)